CASI Pharmaceuticals, Inc.

NasdaqCM:CASI Stock Report

Market Cap: US$39.9m

CASI Pharmaceuticals Management

Management criteria checks 2/4

CASI Pharmaceuticals' CEO is Wei-Wu He, appointed in Apr 2019, has a tenure of 5.67 years. directly owns 5.07% of the company’s shares, worth $2.02M. The average tenure of the management team and the board of directors is 2.4 years and 9.4 years respectively.

Key information

Wei-Wu He

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.7yrs
CEO ownership5.1%
Management average tenure2.4yrs
Board average tenure9.4yrs

Recent management updates

Recent updates

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

Nov 26
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Wei-Wu He's remuneration changed compared to CASI Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$31m

Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023n/an/a

-US$27m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022n/an/a

-US$41m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$10mUS$322k

-US$37m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$819kUS$578k

-US$48m

Sep 30 2020n/an/a

-US$47m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$9mUS$424k

-US$46m

Sep 30 2019n/an/a

-US$43m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$6mn/a

-US$27m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$781kn/a

-US$11m

Compensation vs Market: Insufficient data to establish whether Wei-Wu's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.

CEO

Wei-Wu He (59 yo)

5.7yrs

Tenure

US$9,665,359

Compensation

Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...

Leadership Team

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO5.7yrsUS$9.67m5.07%
$ 2.0m
Alexander A. Zukiwski
Executive VP & Chief Medical Officer7.7yrsUS$1.18mno data
Wei Zhang
Senior Vice Presidentless than a yearUS$2.56m0.013%
$ 5.3k
Daniel Lang
MD, Senior VP & Chief Financial Officerless than a yearno datano data
Chunhua Wang
Chief Operating Officer6.8yrsno datano data
Wei Gao
General Counsel1.9yrsno datano data
James E. Goldschmidt
Chief Business Development Officerno datano datano data
Hai Huang
Global Chief Commercial Officer & GM of CASI Chinaless than a yearno datano data
Amanda Cui
VP & Global Controllerno datano datano data
Kun Qian
VP & Global Controller2.9yrsno datano data

2.4yrs

Average Tenure

56.5yo

Average Age

Experienced Management: CASI's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO12.8yrsUS$9.67m5.07%
$ 2.0m
Sue Eckhardt
Member of Scientific Advisory Board18.4yrsno datano data
Y. Alexander Wu
Independent Director11.7yrsUS$150.50kno data
Thomas Folinsbee
Independent Directorno datano datano data
Ghassan Abou-Alfa
Member of Clinical Advisory Board9.4yrsno datano data
Zhenbo Su
Independent Director1.8yrsno datano data
Robert Mayer
Member of Clinical Advisory Board9.4yrsno datano data
Xuebo Zeng
Independent Director8.9yrsno datano data

9.4yrs

Average Tenure

57.5yo

Average Age

Experienced Board: CASI's board of directors are considered experienced (9.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CASI Pharmaceuticals, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Nathaniel CallowayEdison Investment Research
Ching-Yi LinH.C. Wainwright & Co.